贝诺酯

Benorilate 是对乙酰氨基酚和乙酰水杨酸的酯化产物,具有抗炎、镇痛、解热的作用。Benorilate还能够抑制前列腺素 (PG) 的合成。

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 前列腺素受体

研究领域 >> 炎症/免疫

Prostaglandin[4].

Benorilate是一种酯化阿司匹林制剂,其抗风湿特性据报道与阿司匹林一样好[1]。 Benorylate导致肝脏乳酸转化为葡萄糖的大幅度下降,葡萄糖是葡萄糖稳态的重要组成部分。 Benorylate还会损害氨的尿素合成速率,这是肝脏的另一个重要功能[2]。

Benorylate可能被吸收为完整的分子,这是其良好的胃耐受性[3]。 Benorylate可以抑制实验动物和人体组织中的PG合成[4]。

[1]. Croft DN, et al. Gastric bleeding and benorylate, a new aspirin. Br Med J. 1972 Sep 2;3(5826):545-7.

[2]. Castell JV, et al. Effects of benorylate and impacina on the metabolism of cultured hepatocytes. Xenobiotica. 1985 Aug-Sep;15(8-9):743-9.

[3]. Wright V, et al. A review of benorylate - a new antirheumatic drug. Scand J Rheumatol Suppl. 1975;13:5-8.

[4]. A. Bennett , et al. Inhibition of Prostaglandin Synthesis by Benorylate. Rheumatology, Volume XII, Issue suppl, 1 January 1973, Pages 101-105.

地诺前列酮 | 列腺素 E1 | E7046 | 4-氰基-2-[[2-(4-氟-1-萘基)-1-氧代丙基]氨基]苯基丁酸 | PF-04418948 | 2-(2-甲基-1-(4-(甲基磺酰基)-2-(三氟甲基)苄基)-1H-吡咯并[2,3-b]吡啶-3-基)乙酸 | Grapiprant | TG6-10-1 | Taprenepag | GW627368 | 赛乐西帕中间体 | 雷马曲班 | 6-异丙氧基-9-氧杂蒽酮-2-羧酸 | 拉罗皮兰 | 4-(乙酰氨基)-3-[(4-氯苯基)硫代]-2-甲基-1H-吲哚-1-乙酸

MOLECULAR FORMULA :

C17-H15-N-O5

MOLECULAR WEIGHT :

313.33

WISWESSER LINE NOTATION :

1VOR BVOR DMV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Unreported

SPECIES OBSERVED :

Human - woman

DOSE/DURATION :

1280 mg/kg/8D-I

TOXIC EFFECTS :

Behavioral - hallucinations, distorted perceptions Lungs, Thorax, or Respiration - respiratory stimulation Nutritional and Gross Metabolic - dehydration

REFERENCE :

BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 288,1344,1984

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

3500 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

EPXXDW European Patent Application. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Volume(issue)/page/year: #0080609

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

1830 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #3431293

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

1551 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 28,1692,1978

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

1255 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #3431293 ** REPRODUCTIVE DATA **

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

DOSE :

3960 mg/kg

SEX/DURATION :

female 7-17 day(s) after conception

TOXIC EFFECTS :

Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :

SEIJBO Senten Ijo. Congenital Anomalies. (Nippon Senten Ijo Gakkai, c/o Kinki Daigaku Igakubu Kaibagaku Kyoshitsu, 380 Nishiyama, Sayama-cho, Mirami-Kawachi-gun, Osaka-fu, Japan) V.1-26, 1960-86. For publisher information, see CGANE7. Volume(issue)/page/year: 20,143,1980